Background: Eradication for Helicobacter pylori usually induces digestive dysbiosis that, in turn, elicits symptoms. Consequently, probiotic supplementation may counterbalance the disturbed microbiota after this procedure. So, probiotics may restore microbiota homeostasis quickly relieve complaints. Methods: The current study evaluated the efficacy and safety of Abivisor®, a food supplement containing Lacticaseibacillus rhamnosus LR06 (3 billion living cells), Lactiplantibacillus pentosus LPS01(100 million living cells), Lactiplantibacillus plantarum LP01 (1 billion living cells), and N-acetyl cysteine (60 mg). Patients were randomized into two groups (2:1). Group A took one stick/daily for 60 days after eradication. Group B was considered as control. Patients were evaluated at baseline (T0) and after 15 (T1), 30 (T2), and 60 (T3) days. The severity of digestive symptoms was measured by patients using a Visual Analog Scale. The percentage of patients with each symptom was also evaluated. Results: Abivisor® has significantly and progressively diminished intestinal symptoms' presence and severity at T1, T2, and even more at T3. Accordingly, the percentage of symptomatic patients diminished more rapidly and significantly in group A than in B. All patients well tolerated the food supplement. Conclusions: The present study suggests that Abivisor® may be an effective and safe therapeutic option for managing patients undergoing H. pylori eradication.
Probiotic mixture in patients after Helicobacter pylori eradication: a real-life experience / Aragona, Salvatore E; Fabbri, Carlo; Cammarota, Giovanni; Ciprandi, Giorgio; Leonardo Allegretta, Raffaele Annicchiarico, Antonino Bertino, Stefano Bibbò, Antonio Bordonaro, Carmelo Buda, Federica Calabrese, Salvatore Camilleri, Giuseppe Cautela, Amedeo Cecere, Laura Centenara, Andrea Cocco, Elisabetta Conte, Marco Crovaro, Marianna Cuccu, Enrico Currò, Germana DE Nucci, Emanuele DI Benedetto, Vincenzo DI Martino, Vittorio D'Onofrio, Leonardo H Eusebi, Luciano Ferrini, Giuseppina Ferro, Fabrizio Ficuccilli, Chiara Francia, Girolamo Geraci, Roberto Grassia, Francesco Guardascione, Salvatore Incarbone, Claudio Licci, Andrea Lisotti, Marco Magistroni, Giovanni Magrì, Rita Marquez, Sabina Martini, Luigi Masoni, Vincenzo Mazzuca Mari, Federica Miculan, Alessia Mileti, Carmelo Militello, Leonardo Minelli, Ludovico Montebianco Abenavoli, Federica Morando, Stella Morisco, Domenico Napoletano, Vittorio M Ormando, Antonio Palma, Rossella Palma, Giovanni Papadopoli, Andrea Parodi, Eliseo Pironti, Natale Polimeni, Ivana Raguzzi, Antonella Rigante, Maurizio Romano, Simon Ruggiero, Angelo Sanalitro, Antonella Savastano, Angelo Schicchi, Corrado Selvaggio, Angelo Sigillito, Michele Silla, Eleonora Solida, Mirko Tarocchi, Antonello Trecca, Efisio Trincas, Graziano Troina, Lucy Vannella, Luigi M Vitale, Salvatore Zaru. - In: MINERVA GASTROENTEROLOGY. - ISSN 2724-5985. - ELETTRONICO. - 70:(2024), pp. 197-207. [10.23736/S2724-5985.24.03634-9]
Probiotic mixture in patients after Helicobacter pylori eradication: a real-life experience
Fabbri, Carlo;Vincenzo DI Martino;Carmelo Militello;Mirko Tarocchi;
2024
Abstract
Background: Eradication for Helicobacter pylori usually induces digestive dysbiosis that, in turn, elicits symptoms. Consequently, probiotic supplementation may counterbalance the disturbed microbiota after this procedure. So, probiotics may restore microbiota homeostasis quickly relieve complaints. Methods: The current study evaluated the efficacy and safety of Abivisor®, a food supplement containing Lacticaseibacillus rhamnosus LR06 (3 billion living cells), Lactiplantibacillus pentosus LPS01(100 million living cells), Lactiplantibacillus plantarum LP01 (1 billion living cells), and N-acetyl cysteine (60 mg). Patients were randomized into two groups (2:1). Group A took one stick/daily for 60 days after eradication. Group B was considered as control. Patients were evaluated at baseline (T0) and after 15 (T1), 30 (T2), and 60 (T3) days. The severity of digestive symptoms was measured by patients using a Visual Analog Scale. The percentage of patients with each symptom was also evaluated. Results: Abivisor® has significantly and progressively diminished intestinal symptoms' presence and severity at T1, T2, and even more at T3. Accordingly, the percentage of symptomatic patients diminished more rapidly and significantly in group A than in B. All patients well tolerated the food supplement. Conclusions: The present study suggests that Abivisor® may be an effective and safe therapeutic option for managing patients undergoing H. pylori eradication.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.